Compass Pathways CEO Kabir Nath states that COMP360 will target the estimated 4 million treatment-resistant depression patients who are not currently taking Spravato.

Overview Debates Related claims Topics Sources

The Treatment-Resistant Depression Awareness Day campaign is supported by the National Alliance on Mental Illness, Mental Health America, and the Depression and Bipolar Support Alliance.

Compass Pathways expects COMP360 to be subject to an FDA risk evaluation and mitigation strategy (REMS) upon approval and is investing in provider training for drug administration.

Compass Pathways CEO Kabir Nath stated at the STAT Summit that the company will go slow before it goes fast ahead of the COMP360 FDA submission to avoid early negative patient or provider experiences.

In Compass Pathways Phase 3 trials, roughly 40% of treatment-resistant depression patients experienced a clinically meaningful response after receiving two doses of COMP360 three weeks apart.

Compass Pathways announced the establishment of the first Treatment-Resistant Depression Awareness Day in the U.S. on October 14, 2026.

Compass Pathways CEO Kabir Nath stated on October 14, 2026, that the company plans to complete its rolling FDA submission for COMP360 synthetic psilocybin treatment in the fourth quarter of 2026.

Compass Pathways CEO Kabir Nath stated that COMP360 clinical trial session recordings revealed patients spent approximately 80% of session time in silence after the company deliberately separated psychotherapy from trial protocols.

Compass Pathways is engaging commercial insurers and CMS regarding reimbursement mechanisms for clinical monitoring required during COMP360 psilocybin treatment sessions.

COMP360 psilocybin treatment holds Breakthrough Therapy designation from the U.S. FDA and Innovative Licensing and Access Pathway designation in the UK for treatment-resistant depression.

Definium Therapeutics is developing DT120, an LSD-based formulation that has succeeded in Phase 3 trials for major depressive disorder and generalized anxiety disorder.

Compass Pathways is conducting a rolling submission to the FDA for COMP360, its psilocybin-based candidate for treatment-resistant depression.

COMP360 is designed to slot directly into existing clinic workflows, utilizing the same multidisciplinary staff that currently monitors Spravato patients.

COMP360 succeeded in two Phase 3 clinical trials for treatment-resistant depression, demonstrating durability and clinical efficacy.

Johnson & Johnson's Spravato, an inhaled esketamine treatment approved in 2019, established the clinical infrastructure that Compass Pathways plans to utilize for COMP360.

Jefferies analysts estimate a 75% to 85% chance of FDA approval for COMP360 in 2026, with a potential market launch by the first half of 2027.

Compass Pathways expects the hourly reimbursement rate for COMP360 administration to be higher than the rate currently paid for Spravato.

Compass Pathways established a reimbursement framework to ensure clinics are reimbursed for every hour of the six-to-eight-hour COMP360 observation period.

Compass Pathways expects to complete its FDA rolling submission for COMP360 in the fourth quarter of 2026.

The FDA granted breakthrough therapy designation to DT120 Orally Disintegrating Tablet for the treatment of major depressive disorder based on preliminary clinical evidence.

Definium Therapeutics' phase 3 Emerge study of DT120 Orally Disintegrating Tablet in adults with major depressive disorder showed significant improvement in Montgomery-Åsberg Depression Rating Scale scores at week 6 compared to placebo.